Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.

ABSTRACT: Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigm

SUBMITTER: Reverdy T 

PROVIDER: S-EPMC7564452 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature